RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $708
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $677 to $708.
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $677 to $708.